Gary Bridger

Interim Chief Scientific Officer at Liminal BioSciences

Dr. Bridger has extensive experience in leading research and development through to commercialization. Dr. Bridger previously served as Executive Vice President of Research and Development at Xenon Pharmaceuticals Inc., Senior Vice President of Research and Development of Genzyme Corporation and co-founded AnorMED Inc., eventually acquired by Genzyme.


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Liminal BioSciences

Liminal is a biopharmaceutical corporation supplying state-of-the-art technologies for bio-separations as well as therapeutic products.


Headquarters

Laval, Canada

Employees

201-500

Links